Fortress Biotech (FBIO) Expected to Announce Earnings on Thursday

Fortress Biotech (NASDAQ:FBIO) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Fortress Biotech to post earnings of ($0.79) per share and revenue of $16.30 million for the quarter.

Fortress Biotech Stock Performance

Shares of NASDAQ:FBIO opened at $1.72 on Thursday. The stock has a market capitalization of $47.48 million, a price-to-earnings ratio of -0.56 and a beta of 1.75. Fortress Biotech has a 1-year low of $1.36 and a 1-year high of $2.89. The company has a 50 day moving average price of $1.74 and a 200 day moving average price of $1.79.

Analyst Ratings Changes

Separately, Roth Mkm restated a “buy” rating and issued a $16.00 price target (up previously from $15.00) on shares of Fortress Biotech in a research report on Tuesday, March 11th.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.